This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.
康泰納菲（Cantor Fitzgerald）分析師Louise Chen重申對禮來（Eli Lilly And Co）的股票給予超配（Overweight）評級，並維持885美元的目標股價。
The company is slated to report its second-quarter FY24 earnings on August 8.
公司計劃於2024財年第二季度業績發佈日8月8日公佈其業績。
The analyst highlighted that Eli Lilly's GAAP and non-GAAP financial results for 2Q24 will include acquired IPR&D charges of ~$154 million on a pre-tax basis, representing a charge of ~$0.14 to both GAAP and non-GAAP earnings per share.
該分析師指出，禮來的2024財年第二季度財務報告（GAAP和非GAAP）將包括預稅收購IPR&D的費用約合154百萬美元，這代表GAAP和非GAAP每股收益分別爲0.14美元的費用。
The following are some of the points the analyst lists that are important for the company's growth in the coming days.
以下是分析師列出的一些對公司未來增長至關重要的點。
The analyst expects U.S. approval for Lebrikizumab to treat atopic dermatitis in 2H24E.
該分析師預計，禮來的治療特應性皮炎藥物lebrikizumab將在2024年下半年獲得美國批准。
Also Read: Eli Lilly Announces CFO Change
另外閱讀：禮來宣佈財務長變動
The analyst also expects Morphic acquisition to close in 3Q24. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of IBD.
該分析師還預計，Morphic收購將在2024年第三季度完成。Morphic的主要項目是抑制α4β7整合素的選擇性口服小分子抑制劑，用於治療炎症性腸病。
By the end of 2024, LLY expects to have results of SURMOUNT-5 which is its H2H study of tirzepatide vs. high-dose semaglutide in participants with obesity, said the analyst.
分析師稱，到2024年底，禮來預計將獲得SURMOUNt-5的研究結果，即tirzepatide與高劑量semaglutide在肥胖症患者中的H2H（頭對頭）研究。
The analyst sees the first set of Phase 3 results on orforglipron in T2D/obesity in 2025, from Phase 3 ACHIEVE T2D program.
該分析師預計，從ACHIEVE T2D項目的第3階段“orforglipron”中，第一組T2D/肥胖症的結果將在2025年公佈。
LLY submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. FDA with regulatory action anticipated as early as the end of this year, said the analyst.
分析師稱，禮來已向美國食品和藥物管理局提交了tirzepatide治療中度至重度睡眠呼吸暫停和肥胖症的申請，並預計最早在今年年底獲得監管動作的批准。
Key competitive readouts that the analyst looks forward to include, Novo Nordisk A/S's (NYSE:NVO) semaglutide in MASH, Akero Therapeutics Inc's (NASDAQ:AKRO) efruxifermin (FGF21 analog) in MASH and Novo Nordisk's CagriSema Phase 3 program for obesity.
分析師期待的主要競爭讀數包括Novo Nordisk A/S（納斯達克股票代碼：NVO）的MASH，Akero Therapeutics Inc（NASDAQ股票代碼：AKRO）的efruxifermin（FGF21類似物）在MASH中，以及Novo Nordisk的CagriSema第3期肥胖症方案。
Read Next:
閱讀下文:
- Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
- 艾禮制藥的32億美元Morphic交易是“至關重要的”，儘管投資者關注肥胖症，仍具有“戰略價值”，分析師表示。
Price Action: LLY shares are trading higher by 0.475 at $952.82 at last check Monday.
股價表現：在上週一的最後時刻，LLY股票以952.82美元的價格交易的0.475美元的高點。
Photo by rafapress on Shutterstock
rafaress的shutterstock照片